Ideaya Biosciences receives ODD for Darovasertib for treating uveal melanoma EP News Bureau May 3, 2022 Under the ODD, Ideaya may be entitled to certain tax credits, exemption from user fees, and seven years of statutory marketing…
Ideaya and Pfizer expand clinical trial collaboration and supply agreements EP News Bureau Mar 15, 2022 The step is taken to evaluate Darovasertib and Crizotinib combination in Metastatic Uveal Melanoma and additional cMET-driven…
